The Nuveen Core Plus Impact Fund (NPCT) is considered a sell because it pays out more than it earns, relying heavily on return of capital rather than net investment income. Its high leverage of 36.73% and aggressive dividend payouts are eroding its net asset value (NAV), with a potential 25% dividend cut needed to stabilize the fund. The fund's growth depends on lower interest rates, but until then, NAV destruction and limited upside make it an unattractive investment currently.
TGS ASA has secured a large 4D streamer contract offshore Angola, set to begin data acquisition in early July 2026 and last about eight months. This contract strengthens TGS's strategic presence in Africa and ensures vessel utilization into early 202...
argenx, a global immunology company focused on autoimmune diseases, announced its management team will present at two key investor conferences in June: the William Blair 46th Annual Growth Stock Conference and the Goldman Sachs 47th Annual Global Hea...
Roche has introduced the Liver Disease Panel, the first comprehensive set of certified algorithms designed to improve the detection and management of chronic liver disease (CLD). This panel includes LiverPRO, an algorithm that uses routine blood mark...
Capgemini unveiled its 2028 strategic plan focusing on leveraging AI agent technology to drive business transformation for large enterprises. The company aims for a 5.5% to 7.5% annual revenue growth from 2025 to 2028, with about 2 points from merger...
Capgemini announced its strategic direction focused on leveraging agentic AI to drive enterprise-wide transformation and business value. The company aims for a 5.5% to 7.5% compound annual revenue growth rate from 2025 to 2028, with margin expansion ...
